Want to see HK:3737 full AI Analyst Report?
Top Page
Zhongzhi Pharmaceutical Holdings Limited
(3737)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.72
▼(-17.73% Downside)
Action:Reiterated
Date:07/25/26
The score is held back primarily by sharp 2025 operational deterioration (revenue decline and major margin compression) and weak technical positioning (below major moving averages with negative MACD). Offsetting factors are a relatively low-leverage balance sheet and a high dividend yield, though the P/E remains elevated relative to the weakened earnings profile.
Positive Factors
Conservative Leverage
Modest debt relative to equity provides financial resilience and limits balance-sheet risk as the company navigates weaker profitability. A stable equity base also preserves flexibility to support operations and fund investment without relying heavily on additional borrowing.
Negative Factors
Revenue Contraction
The sharp revenue decline signals weaker demand, market execution, or product performance and reduces the scale available to absorb fixed operating costs. Unless growth recovers, sustained contraction could pressure investment capacity and make future earnings less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Leverage
Modest debt relative to equity provides financial resilience and limits balance-sheet risk as the company navigates weaker profitability. A stable equity base also preserves flexibility to support operations and fund investment without relying heavily on additional borrowing.
Read all positive factors
Zhongzhi Pharmaceutical Holdings Limited (3737) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$605.60M
Dividend Yield6.99%
Average Volume (3M)382.23K
Price to Earnings (P/E)28.5
Beta (1Y)0.10
Revenue Growth-15.17%
EPS Growth-12.17%
CountryHK
Employees2,168
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding863,600,000
10 Day Avg. Volume406,700
30 Day Avg. Volume382,233
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.38
Price to Sales (P/S)0.24
P/FCF Ratio5.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhongzhi Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operatio...
Zhongzhi Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.74B | 2.21B | 2.05B | 1.83B | 1.75B |
| Gross Profit | 875.92M | 940.25M | 1.29B | 1.22B | 1.07B | 1.06B |
| EBITDA | 68.36M | 55.28M | 170.39M | 317.53M | 153.87M | 119.71M |
| Net Income | 17.62M | 17.29M | 95.21M | 162.78M | 106.39M | 52.13M |
Balance Sheet | ||||||
| Total Assets | 1.76B | 1.83B | 1.99B | 1.79B | 1.88B | 1.52B |
| Cash, Cash Equivalents and Short-Term Investments | 185.38M | 200.89M | 167.10M | 166.65M | 419.36M | 242.18M |
| Total Debt | 87.63M | 227.02M | 188.60M | 225.06M | 170.86M | 175.74M |
| Total Liabilities | 655.45M | 732.02M | 865.58M | 739.30M | 869.31M | 622.94M |
| Stockholders Equity | 1.10B | 1.10B | 1.12B | 1.05B | 1.00B | 898.74M |
Cash Flow | ||||||
| Free Cash Flow | -57.46M | 69.88M | 39.62M | -69.93M | 196.17M | -7.47M |
| Operating Cash Flow | -41.85M | 104.19M | 181.48M | 101.50M | 284.57M | 178.38M |
| Investing Cash Flow | -4.59M | -52.73M | -120.06M | -202.76M | 13.38M | -135.98M |
| Financing Cash Flow | -25.62M | -117.07M | -58.73M | -154.62M | -68.14M | -40.83M |
Zhongzhi Pharmaceutical Holdings Limited Technical Analysis
Positive
0.88
Price Trends
0.67
Positive
0.72
Negative
0.72
Negative
Market Momentum
0.01
Negative
55.13
Neutral
58.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3737, the sentiment is Positive. The current price of 0.88 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.67, and above the 200-day MA of 0.72, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 55.13 is Neutral, neither overbought nor oversold. The STOCH value of 58.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3737.
Zhongzhi Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$779.10M | 7.75 | 13.59% | 7.40% | 10.63% | 39.44% | |
65 Neutral | HK$703.66M | 4.73 | 7.52% | 4.96% | 7.05% | 22.46% | |
54 Neutral | HK$605.60M | 28.51 | 1.60% | 6.99% | -15.17% | -12.17% | |
54 Neutral | HK$226.20M | -0.19 | -154.56% | ― | -7.12% | -523.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$345.46M | 86.11 | 0.34% | 84.69% | -8.30% | -44.44% | |
41 Neutral | HK$718.63M | -9.37 | 14.19% | 0.02% | 100.34% | 83.97% |
* Healthcare Sector Average
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.71
0.02
2.90%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
-0.04
-36.13%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.05
-13.89%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.23
-0.84
-40.82%
HK:1011
China NT Pharma Group Co., Ltd.
0.39
-0.82
-67.77%
HK:0239
Pak Fah Yeow International Limited
2.48
0.17
7.27%
Zhongzhi Pharmaceutical Holdings Limited Corporate Events
Zhongzhi Pharmaceutical Posts Lower Revenue but Slight Profit Gain in First Half 2026
Aug 26, 2026
Zhongzhi Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands, focuses on manufacturing and selling pharmaceutical products in the Chinese market. The company derives its revenue primarily fro...
Zhongzhi Pharmaceutical Sets Board Meeting to Review Interim Results and Possible Dividend
Aug 14, 2026
Zhongzhi Pharmaceutical Holdings Limited has scheduled a board meeting in Hong Kong on 26 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. At the same meeting, directors will also consider the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.